Organisation paid for research Program year 2025 Source: CMS Open Payments

The West Clinic PC

Neither a doctor nor a teaching hospital

Research payments

$2,369,817

653 payments

Through program year 2025, The West Clinic PC is reported as receiving $2,369,817 in research payments, across 653 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$689,063	158
2024	Research	$512,519	130
2023	Research	$496,399	89
2022	Research	$124,012	31
2021	Research	$144,463	109
2020	Research	$134,352	81
2019	Research	$269,009	55

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $843,167 188 payments
BioNTech SE $495,787 102 payments
Hoffmann-La Roche Limited $348,117 87 payments
Amgen Inc. $198,767 3 payments
EMD Serono, Inc. $128,529 78 payments
Incyte Corporation $126,359 127 payments
Pfizer Inc. $75,281 21 payments
Gilead Sciences, Inc. $44,347 21 payments
E.R. Squibb & Sons, L.L.C. $21,717 1 payment
Merck Sharp & Dohme Corporation $21,030 1 payment

Studies the money was for Research payments · program years 2019–2025

Bnt327-02 $335,778 71 payments
PH 1A 1B of Accr8 in Solid Tumors $332,466 36 payments
Morpheus TNBC $217,012 34 payments
Phase III Study of Giredestrant Everolimus VS Everolimus Exemestane in Er Her2 Locally Adv Or MBC $176,081 60 payments
Bnt327 $160,009 31 payments
Morpheus Breast Cancer $131,105 53 payments
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients $114,071 10 payments
A Phase 1b trial of talimogene laherparepvec in combination with dabrafenib and trametinib in advanced melanoma with an activating BRAF mutation $99,254 1 payment
Single Agent GDC 9545 VS Endocrine Monotherapy Adjuvant Treatment in HR Ebc $89,266 44 payments
P1/3 talimogene laherparepvec + MK-3475 Combo melanoma $88,884 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.